This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by You, L. Articles by Jablons, D. M. Search for Related Content PubMed PubMed Citation Articles by You, L. Articles by Jablons, D. M.

An Anti-Wnt-2 Monoclonal Antibody Induces Apoptosis in Malignant Melanoma Cells and Inhibits Tumor Growth

¹ Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, ² Department of Pharmaceutical Chemistry, and ³ Auerback Melanoma Research Laboratory, Department of Dermatology, University of California, San Francisco, California

Activation of the Wnt/ß-catenin signaling pathway has been associated with human cancers. To test whether Wnt-2 signal is a survival factor in human melanoma cells and thus represents a potential therapeutic target, we investigated the effects of inhibition of Wnt-2 signaling in human melanoma cell lines. We have developed a novel monoclonal antibody against the NH₂ terminus of the human Wnt-2 ligand that induces apoptosis in human melanoma cells overexpressing Wnt-2. Whereas incubation of this antibody with normal cells lacking Wnt-2 expression does not induce apoptosis, Wnt-2 signaling blockade by the ligand-binding antibody is confirmed by down-regulation of Dishevelled and ß-catenin. Wnt-2 small interfering RNA treatment in these cells yielded similar apoptotic effects and downstream changes. Down-regulation of an inhibitor of apoptosis family protein, survivin, was observed in both the Wnt-2 antibody-treated and small interfering RNA-treated melanoma cell lines, suggesting that the antibody induces apoptosis by inactivating survivin. In an in vivo study, this monoclonal anti-Wnt-2 antibody suppresses tumor growth in a xenograft model. These findings suggest that the anti-Wnt-2 monoclonal antibody may be useful for the treatment of patients with malignant melanoma.

This article has been cited by other articles:

				N. Taniguchi, B. Carames, Y. Kawakami, B. A. Amendt, S. Komiya, and M. Lotz Chromatin protein HMGB2 regulates articular cartilage surface maintenance via {beta}-catenin pathway PNAS, September 29, 2009; 106(39): 16817 - 16822. [Abstract] [Full Text] [PDF]

				C.-C. Liu, C. Pearson, and G. Bu Cooperative Folding and Ligand-binding Properties of LRP6 {beta}-Propeller Domains J. Biol. Chem., May 29, 2009; 284(22): 15299 - 15307. [Abstract] [Full Text] [PDF]

				M. Kashani-Sabet, J. Rangel, S. Torabian, M. Nosrati, J. Simko, D. M. Jablons, D. H. Moore, C. Haqq, J. R. Miller III, and R. W. Sagebiel A multi-marker assay to distinguish malignant melanomas from benign nevi PNAS, April 14, 2009; 106(15): 6268 - 6272. [Abstract] [Full Text] [PDF]

				T. John, M. A. Black, T. T. Toro, D. Leader, C. A. Gedye, I. D. Davis, P. J. Guilford, and J. S. Cebon Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma Clin. Cancer Res., August 15, 2008; 14(16): 5173 - 5180. [Abstract] [Full Text] [PDF]

				L. You, Z. Xu, C. Punchihewa, D. M. Jablons, and N. Fujii Evaluation of a chemical library of small-molecule Dishevelled antagonists that suppress tumor growth by down-regulating T-cell factor-mediated transcription Mol. Cancer Ther., June 1, 2008; 7(6): 1633 - 1638. [Abstract] [Full Text] [PDF]

				E. Ortega-Paino, J. Fransson, S. Ek, and C. A. K. Borrebaeck Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference Blood, February 1, 2008; 111(3): 1617 - 1624. [Abstract] [Full Text] [PDF]

				L. Queimado, D. Obeso, M. D. Hatfield, Y. Yang, D. M. Thompson, and A. M.C. Reis Dysregulation of Wnt Pathway Components in Human Salivary Gland Tumors Arch Otolaryngol Head Neck Surg, January 1, 2008; 134(1): 94 - 101. [Abstract] [Full Text] [PDF]

				T. F. Gajewski, E. A. Grimm, B. J. Nickoloff, and A. T. Weeraratna New Potential Therapeutic Targets in Melanoma ASCO Educational Book, January 1, 2008; 2008(1): 404 - 407. [Abstract] [Full Text] [PDF]

				V. I. DeAlmeida, L. Miao, J. A. Ernst, H. Koeppen, P. Polakis, and B. Rubinfeld The Soluble Wnt Receptor Frizzled8CRD-hFc Inhibits the Growth of Teratocarcinomas In vivo Cancer Res., June 1, 2007; 67(11): 5371 - 5379. [Abstract] [Full Text] [PDF]